Related Experiment Video
Updated: Mar 27, 2026
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Long Non-coding RNAs and Drug Resistance
Jing-Jing Pan1, Xiao-Juan Xie, Xu Li
1Clinical Laboratory, the First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China
Background:
Long non-coding RNAs (lncRNAs) are emerging as key players in gene expression that govern cell developmental processes, and thus contributing to diseases, especially cancers. Many studies have suggested that aberrant expression of lncRNAs is responsible for drug resistance, a substantial obstacle for cancer therapy. Drug resistance not only results from individual variations in patients, but also from genetic and epigenetic differences in tumors. It is reported that drug resistance is tightly modulated by lncRNAs which change the stability and translation of mRNAs encoding factors involved in cell survival, proliferation, and drug metabolism. In this review, we summarize recent advances in research on lncRNAs associated with drug resistance and underlying molecular or cellular mechanisms, which may contribute helpful approaches for the development of new therapeutic strategies to overcome treatment failure.
Insights
Long non-coding RNAs (lncRNAs) are crucial in gene expression and cancer development. Aberrant lncRNA expression drives drug resistance, hindering cancer therapy and necessitating new treatment strategies.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Long non-coding RNAs (lncRNAs) regulate gene expression and cell development.
- Aberrant lncRNA expression is linked to cancer and drug resistance.
- lncRNAs modulate mRNA stability and translation impacting cell survival and drug metabolism.
Purpose of the Study:
- To review recent advances in lncRNAs associated with drug resistance.
- To summarize molecular and cellular mechanisms of lncRNA-mediated drug resistance.
- To explore therapeutic strategies to overcome treatment failure in cancer.
Main Methods:
- Literature review of studies on lncRNAs and drug resistance.
- Analysis of molecular mechanisms.
- Synthesis of cellular pathways involved.
Main Results:
- lncRNAs play a significant role in the development of cancer drug resistance.
- Specific lncRNAs modulate key factors for cell survival, proliferation, and drug metabolism.
- Understanding these mechanisms offers potential therapeutic targets.
Conclusions:
- lncRNAs are critical regulators in cancer drug resistance.
- Targeting lncRNAs presents a promising avenue for novel cancer therapies.
- Further research into lncRNA mechanisms can overcome treatment failure.
More Related Videos
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:39lncRNA - Long Non-coding RNAs
02:56Treatment Resistant Cancers
01:20Types of RNA
RNA Performs Diverse...
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
03:18Non-LTR Retrotransposons